Semaglutide: GLP-1 Receptor Research and Trial Record

Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1), modified to have a long half-life so it can work as a once-weekly agonist. More than any other single compound, it brought incretin biology into everyday conversation. There is a large body of human research. This is an educational summary of it, and research-grade material is for laboratory Research Use Only.

A GLP-1 agonist that lasts

GLP-1 is an incretin hormone that ties nutrient sensing in the gut to insulin signaling and satiety. Reviews describe how semaglutide was developed from the native hormone into a stable, long-acting analog (Knudsen & Lau, Front Endocrinol, 2019). [1] Related work produced a version that can be absorbed by mouth, which is a hard thing to do with a peptide (Buckley et al., Sci Transl Med, 2018). [2]

The human trial record

The STEP program tested semaglutide for body-weight outcomes in people with overweight or obesity (Wilding et al., N Engl J Med, 2021). [3] This large set of trials is why semaglutide is the reference point in so much metabolic research.

Approval status

Semaglutide is an FDA-approved drug: Ozempic (2017), Rybelsus (2019, the oral form) and Wegovy (2021). That approval covers the pharmaceutical products. It does not cover research-grade material.

Note: Human trial data do not turn research material into a medicine or permit human use. Trials use pharmaceutical-grade drug under supervision. Research-grade material is for laboratory Research Use Only and is not for human or veterinary use.

FAQ

Is semaglutide a peptide?

Yes. It is a synthetic analog of the GLP-1 peptide hormone, changed so it resists breakdown and acts over a longer period.

References

1. Knudsen & Lau — discovery & development of semaglutide (Front Endocrinol, 2019)
2. Buckley et al. — oral semaglutide absorption (Sci Transl Med, 2018)
3. Wilding et al. — STEP 1, semaglutide & body weight (NEJM, 2021)
4. Tirzepatide guide (dual-receptor agonist)